CAS: 16681-59-7; 2-Bromo-1-Methyl-1H-Imidazole

相似化合物

1207457-15-5 53857-60-6 663171-12-8

上下游产品

CAS号616-47-7 N-甲基咪唑 | CAS号60-56-0 甲巯咪唑 | CAS号53857-59-3 2,5-二溴-1-甲基-1H-咪唑 | CAS号225385-11-5 7-chloro-2-(1-m... | CAS号77429-59-5 2-(1-methylimid... | CAS号141989-38-0 4-(1-methylimid... | CAS号52755-94-9 2-(1-甲基-1H-咪唑)-2-苯酚

📜N-甲基咪唑置于溴化氰体系中,用 乙腈 用作溶剂,化学反应 3.0H,以64%的收率获得2-溴-1-甲基-1H-咪唑
参考文献:Reaction Of Imidazoles With Cyanogen Bromide: Cyanation At N 1 Or Bromination At C 2
标题:Reaction Of Imidazoles With Cyanogen Bromide: Cyanation At N 1 Or Bromination At C 2
摘要:一些咪唑(1H-,1-甲基-,2-甲基-,4-甲基-,1,2-,1,4-和 1,5-二甲基-,1-乙基-,1-苄基-和 1-丁基-咪唑)在乙腈溶液中发生反应,和 1-丁基咪唑)以及咪唑与 Brcn 的络合物([co(Nh3)5(Imh)](Clo4)3,[co(Nh3)5(Im)](Clo4)2 和[co(Nh3)5(1-Meim)](Clo4)3)进行了研究.带有 N-烷基取代基和 C2 位有氢的咪唑反应反应生成2-溴产物,而 N-H-咪唑反应反应生成N-氰基衍生物.1,2-二甲基咪唑与 Brcn 反应生成的产物无法定性.在这些复合物中,只有[co(Nh3)5(Im)](Clo4)2 发生反应,反应生成2-溴产物.我们的观察结果表明,咪唑与 Brcn 反应需要环氮原子上的孤对子,并提出了一种可能的机理.报告了 2-甲基咪唑-1-甲腈的 X 射线结构.晶体数据(-143oc)为 C5H5N3:单斜,P21/c,A10-201(5),B 7-110(3),C 7-227(3) å,β 100-47(2)°,V 515-4(4) å 3,Z 4,Dcalcd 1-380 Gcm¯3 .对所有 1278 个数据的细化结构收敛于 Fo >4F(Fo) 的 1183 次反射的 R1 0-0444 和 Wr2 0-1259.
Doi:10.1071/c98105

专利信息

专利号:US-11767302-B2
优先权日:2020-10-01
标题 :Reagents and methods for tetrazine synthesis
发明人：FOX JOSEPH M; LAMBERT WILLIAM; FANG YINZHI; AM ENDE CHRISTOPHER WILLIAM; MAHAPATRA SUBHAM; XIE YIXIN; WANG CHUANQI
权利人:UNIV DELAWARE
摘要:Disclosed herein are mono- and di-substituted tetrazines and methods of their preparation and converting an oxetanyl ester to a thio-substituted tetrazine, which is then converted to a mono-substituted tetrazine, a di-substituted tetrazine, or a vinylether disubstituted tetrazine.

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:CN-117683016-A
优先权日:2022-09-05
标 题:Synthesis of Chiral 3,4-Disubstituted Aminopyridine Catalyst and Its Application in Black Rearrangement

专利号:US-8445510-B2
优先权日:2010-05-14
标题 :Fused bicyclic kinase inhibitors
发明人：MULVIHILL MARK J; STEINIG ARNO G; CREW ANDREW PHILIP; JIN MEIZHONG; KLEINBERG ANDREW; LI AN-HU; WANG JING
权利人:MULVIHILL MARK J; STEINIG ARNO G; CREW ANDREW PHILIP; JIN MEIZHONG; KLEINBERG ANDREW; LI AN-HU; WANG JING; OSI PHARMACEUTICALS LLC
摘要:Compounds of Formula I, as shown below and defined herein: n n n n n n n n n n pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.